Scholar Rock(SRRK) - 2023 Q3 - Earnings Call Presentation

Ted Myles, MBA Chief Operating Officer & Chief Financial Officer • Developing a novel, highly potent and selective antibody (SRK-439) for cardiometabolic disorders Dose Escalation (3+3) Cohort NSCLC 9 0 10 20 30 40 0 1000 2000 3000 Post Treatment % CD8 Positive Tumor nest size (cell count) Excluded Infiltrated Post-Treatment Pre-Treatment • 10 SD patients, 5 of which remain on study © 2023 Scholar Rock, Inc. All rights reserved. | --- | --- | |--------------------|-------| | | | | | | | | | | | | | | | | | ...